Detail akcie Theralase Tech Inc online

Business Summary: Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which researches, develops, manufactures and distributes cool laser therapy systems to healthcare practitioners, predominantly for the healing of pain.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Theralase Technologies Inc revenues increased 12% to C$311K. Net loss applicable to common stockholders increased 1% to C$2.4M. Revenues reflect Canada segment increase of 38% to C$286K. Higher net loss reflects Stock Based Compensation increase of 59% to C$222K (expense), General and administrative expenses increase of 99% to C$118K (expense).